Austin Gipson
Family · Fort Worth, TXNPI 1043995673
Payments from drug & device makers
Across 28 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
- AstraZeneca$92
- Otsuka America Pharmaceutical, Inc.$66
- Lundbeck LLC$64
- Johnson & Johnson$36
- Axsome Therapeutics, Inc.$33
- plus $84 from 4 others
What the payments were for
- Food & beverage$526100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $151 |
| AstraZeneca | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Lundbeck LLC | 3 | $64 |
| Johnson & Johnson | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Corium, LLC | 1 | $32 |
| Lilly USA, LLC | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Medtronic | 1 | $15 |
How this compares
$526 in reported general payments places this provider in the 55th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $5,006 |
| Fluticasone Propionate | 30 | $532 |
| Atorvastatin Calcium | 55 | $462 |
| Pantoprazole Sodium | 40 | $453 |
| Levothyroxine Sodium | 57 | $441 |
| Methocarbamol | 23 | $432 |
| Hydroxyzine Hcl | 17 | $355 |
| Gabapentin | 25 | $347 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $297 |
| Nifedipine ErNifedipine | 13 | $285 |
| Omeprazole | 14 | $267 |
| Rosuvastatin Calcium | 18 | $260 |
| Pravastatin Sodium | 12 | $236 |
| Methylprednisolone | 33 | $222 |
| Metformin Hcl | 29 | $180 |
Paid to pharmacies, not to this prescriber.
Other family in Fort Worth
- Laura MoeFort Worth$158K
- Julie TaylorFort Worth$63K
- Ryan BourgeoisFort Worth$37K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.